Toxicity and compliance with a chemoradiotherapy schedule for advanced nasopharyngeal carcinoma: a single institution experience using the Intergroup 0099 study regimen.
Chajón
Enrique A
EA
García-Berrocal
Maria Isabel
MI
De la Fuente
Cristina
C
Regueiro
Carlos
C
Romero
Jesús
J
Valcárcel
Francisco
F
Magallón
Rosa
R
Hernanz
Raúl
R
De la Torre
Alejandro
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001071:Appointments and Schedules; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D010349:Patient Compliance / Q000706:statistics & numerical data*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome